| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w21233 |
| 来源ID | Working Paper 21233 |
| An Overview of the Stratified Economics of Stratified Medicine | |
| Mark R. Trusheim; Ernst R. Berndt | |
| 发表日期 | 2015-06-08 |
| 出版年 | 2015 |
| 语种 | 英语 |
| 摘要 | The economics of stratified medicine depend critically on setting the cut-off score of the companion diagnostic (CDx). This action integrates scientific, clinical, ethical and commercial considerations, and simultaneously determines the value of the stratified medicine to developers, providers, payers and patient. Setting a high cut-off ensures a larger response by excluding more non-responders but also denies treatment to patients who would respond. This creates ethical and clinical concerns, and limits market size. Setting a low cut-off includes more patients who can benefit but includes more non-responders with commensurate costs, side effects and lost time. CDx’s capture little value under current reimbursement and exclusivity protections. Combined with low CDx investment incentives for generic drug manufacturers, little CDx development occurs for older legacy drugs. Therefore payers face an asymmetric situation of novel stratified medicines raising public health and payers’ costs, but no CDx’s for legacy treatments to reduce costs. It would be in payers’ interests to rediscover their heritage of direct investment in diagnostic development. |
| 主题 | Microeconomics ; Households and Firms ; Health, Education, and Welfare ; Health ; Industrial Organization ; Market Structure and Firm Performance ; Industry Studies |
| URL | https://www.nber.org/papers/w21233 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/578908 |
| 推荐引用方式 GB/T 7714 | Mark R. Trusheim,Ernst R. Berndt. An Overview of the Stratified Economics of Stratified Medicine. 2015. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
